loading...| Preferred Name |
Olaparib |
|
| Synonyms |
PARP inhibitor AZD2281 PARP Inhibitor AZD2281 AZD 2281 AZD-2281 AZD2281 KU-0059436 Lynparza OLAPARIB Olanib Olaparib Olaparix olaparib |
|
| Definitions |
A small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Olaparib selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C71721 |
|
| Accepted_Therapeutic_Use_For |
adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer; deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer |
|
| ALT_DEFINITION |
A substance being studied in the treatment of breast, ovarian, and prostate cancers caused by mutations (changes) in the BRCA1 and BRCA2 genes. It is also being studied in the treatment of other types of cancer. It blocks an enzyme involved in many functions of the cell, including the repair of DNA damage. DNA damage may be caused by normal cell actions, UV light, some anticancer drugs, and radiation used to treat cancer. AZD2281 may cause cancer cells to die. It is a type of targeted therapy agent and a type of poly (ADP-ribose) polymerase inhibitor. |
|
| CAS_Registry |
763113-22-0 |
|
| Chemical_Formula |
C24H23FN4O3 |
|
| code |
C71721 |
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
| Contributing_Source |
CTRP FDA GDC HemOnc |
|
| DEFINITION |
A small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Olaparib selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks. |
|
| Display_Name |
Olaparib |
|
| FDA_UNII_Code |
WOH1JD9AR8 |
|
| FULL_SYN |
PARP inhibitor AZD2281 PARP Inhibitor AZD2281 AZD 2281 AZD-2281 AZD2281 KU-0059436 Lynparza OLAPARIB Olanib Olaparib Olaparix olaparib |
|
| Has_Target |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C48215 |
|
| Is_Value_For_GDC_Property | ||
| label |
Olaparib |
|
| Legacy Concept Name |
PARP_Inhibitor_AZD2281 |
|
| Maps_To |
Olaparib |
|
| NCI_Drug_Dictionary_ID |
560191 |
|
| PDQ_Closed_Trial_Search_ID |
560191 |
|
| PDQ_Open_Trial_Search_ID |
560191 |
|
| Preferred_Name |
Olaparib |
|
| prefixIRI |
Thesaurus:C71721 |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C2316164 |
|
| subClassOf |